Skip to main content

Advertisement

Table 2 Odds ratios (OR) and 95% confidence intervals (CI) for specific cancers1 versus all other subjects (controls)2 by tertile of virus antibody measure in the controls

From: Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: A case control study

Virus and cancer group Control tertiles Cases/Controls OR 95% CI P-trend
HSV-1 and Oral cancer 0–5.04 23/200 1.00   
  5.05–6.07 26/199 1.06 (0.6 – 2.0)  
  6.08+ 31/199 1.28 (0.7 – 2.3) 0.40
HSV-2 and Cervical cancer 0–1.08 11/91 1.00   
  1.09–2.17 11/91 0.90 (0.4 – 2.2)  
  2.18+ 23/90 1.82 (0.8 – 4.1) 0.10
EBV-EBNA and non-Hodgkin lymphoma 0–3.81 24/208 1.00   
  3.82–5.29 31/203 1.32 (0.7 – 2.4)  
  5.30+ 22/211 0.87 (0.4 – 1.8) 0.80
EBV-EBNA and Hodgkin lymphoma 0–3.87 33/211 1.00   
  3.88–5.31 18/208 0.49 (0.3 – 0.96)  
  5.32+ 21/208 0.66 (0.3 – 1.4) 0.19
HHV-6 and Oral cancer 0–1.59 16/195 1.00   
  1.60–2.43 28/194 1.83 (0.9 – 3.6)  
  2.44+ 31/195 2.21 (1.1 – 4.3) 0.02
HHV-6 and Hodgkin lymphoma 0–1.58 21/172 1.00   
(excluding oral cancers) 1.59–2.40 17/174 0.87 (0.4 – 1.7)  
  2.41+ 28/172 1.32 (0.7 – 2.5) 0.39
HHV-6 and Myeloid Leukaemia 0–1.61 47/131 1.00   
(excluding oral cancers) 1.62–2.59 52/134 1.16 (0.7 – 1.9)  
  2.60+ 26/131 0.58 (0.3 – 1.0) 0.03
  1. 1For associations that had been reported previously.
  2. 2 The control group in these analyses included all other subjects, except patients with multiple myeloma, because in general mean antibody levels did not vary significantly across disease groups after exclusion of subjects with multiple myeloma (Figure 1), and including all patients increased the power of these analyses.
  3. All analyses are adjusted for age group, sex, day of assay and assay plate.